The effect of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke: A clinical trial

The effect of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke: A clinical trial

Background and Aim: Edaravone is known for its efficacy in inhibiting free radical formation, activating microglia, and promoting neurogenesis and neuroprotection following acute ischemic stroke. This clinical trial aimed to investigate the effects of Edaravone on clinical symptoms and oxidative str...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mojtaba Khazaei, Fatemeh Saadati Pour, Masoud Ghiasian, Salman Khazaei, Shahir Mazaheri, Akram Ranjbar, Sajjad Daneshyar, Mozhgan Nazifi
Format:	Article
Language:	fas
Published:	Kashan University of Medical Sciences 2024-04-01
Series:	مجله علوم پزشکی فیض (پیوسته)
Subjects:	acute ischemic stroke edaravone oxidative stress antioxidants
Online Access:	http://feyz.kaums.ac.ir/article-1-5105-en.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Edaravone's Safety Profile in Acute Ischemic Stroke
by: Laurence K. J. Batino, et al.
Published: (2024-12-01)

Antioxidant and Apoptotic Effect of Edaravone on Cisplatin-Induced Brain Injury in Rats
by: Ozlem Kara, et al.
Published: (2024-01-01)

Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
by: Qian Chen, et al.
Published: (2022-04-01)

Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data
by: Yukari Ogawa, et al.
Published: (2025-01-01)

Corrigendum: Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage
by: Qian Chen, et al.
Published: (2024-12-01)

Edaravone dexborneol compared to edaravone in the treatment of acute cerebral infarction: A meta-analysis
by: Yanshuo Shi, et al.
Published: (2025-06-01)

Diffusion constraints in neuroprotection: implications for clinical trials
by: Daniil P. Aksenov, et al.
Published: (2025-03-01)

The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model
by: Yasin Bagheri, et al.
Published: (2024-12-01)

Emergence of acute quadriparesis in a young patient following myocardial infarction. A case report
by: Sajjad Daneshyar, et al.
Published: (2024-09-01)

Development and Validation of a Stability-Indicating RP-HPLC Method for Edaravone Quantification
by: Riuna O’Neill, et al.
Published: (2025-07-01)

Edaravone dexborneol provides neuroprotective benefits by suppressing ferroptosis in experimental intracerebral hemorrhage
by: Han Li, et al.
Published: (2025-05-01)

Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis
by: Mei Li, et al.
Published: (2024-11-01)

Edaravone Attenuates Sleep Deprivation-Induced Memory Deficits by Inhibiting Oxidative Stress and Neuroinflammation in Murine Models
by: Shiliang Ji, et al.
Published: (2025-04-01)

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
by: Chang Liu, et al.
Published: (2024-10-01)

Adverse events reporting of edaravone: a real-world analysis from FAERS database
by: Qi Shang, et al.
Published: (2025-03-01)

Peculiarities of neuroprotective therapy in women with acute ischemic stroke
by: O. A. Halushko, et al.
Published: (2020-08-01)

Edaravone dexborneol alleviates pericyte-mediated fibrosis depositing extracellular matrix through TGF-β1/IL-11 in cerebral small vessel disease
by: Qingrui Duan, et al.
Published: (2025-02-01)

Edaravone Dexborneol provides neuroprotective effect by inhibiting neurotoxic activation of astrocytes through inhibiting NF-κB signaling in cortical ischemia
by: Zhe Chen, et al.
Published: (2024-11-01)

Edaravone reduces the markers of oxidative stress and neuroinflammation in neocortex of rats with acute intracerebral hemorrhage and type 2 diabetes mellitus
by: V. L. Holubiev, et al.
Published: (2024-12-01)

Oligoclonal band on the 5-year prognosis of patients with multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2025-03-01)

Neuroprotective effect and possible mechanism of edaravone in rat models of spinal cord injury: a systematic review and network meta-analysis
by: Long-yun Zhou, et al.
Published: (2025-04-01)

Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice
by: Rui Mao, et al.
Published: (2025-06-01)

Edaravone dexborneol protected neurological function by targeting NRF2/ARE and NF-κB/AIM2 pathways in cerebral ischemia/reperfusion injury
by: Hui Zhang, et al.
Published: (2025-04-01)

Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis
by: James D Berry, et al.
Published: (2025-01-01)

Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis
by: Yuchen Wang, et al.
Published: (2025-01-01)

Analysis of Clinical Rehabilitation of Ischemic Stroke
by: Zhouting FU, et al.
Published: (2017-12-01)

A Highly Potent Apomorphine Derivative Enhancing Neurite Outgrowth via Nrf2 Activation
by: Tamaki Ishima, et al.
Published: (2025-04-01)

Clinical and neurophysiological peculiarities in patients with ischemic supratentorial stroke
by: A. A. Kuznietsov
Published: (2013-08-01)

Transient Ischemic Attack: Clinical Features and Outcome
by: Desislava Drenska, et al.
Published: (2017-11-01)

SAFETY OF TIROFIBAN FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN ROUTINE CLINICAL PRACTICE
by: Yan-Jun Zhang, et al.
Published: (2014-04-01)

Effect of hypertension on clinical outcomes in ischemic colitis
by: Huahui Zhang, et al.
Published: (2025-12-01)

PREINFARCTION ANGINA AS A CLINICAL FORM OF THE ISCHEMIC PRECONDITIONING PHENOMENON
by: E. A. Lykasova, et al.
Published: (2014-06-01)

Clinical and pathophysiological foundations and advanced developments in the rehabilitation of patients after ischemic stroke
by: E. G. Demianovskaia, et al.
Published: (2021-07-01)

Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)
by: T. M. Alekseeva, et al.
Published: (2019-01-01)

Evaluation of Recurrence of Ischemic Stroke and Transient Ischemic Attack Three Months After the First Transient Ischemic Attack Based On Diffusion-Weighted Imaging (DWI)
by: Abolfazl Atalu, et al.
Published: (2023-04-01)

Clinical and epidemiological overview of hyperacute ischemic stroke patients treated with intravenous thrombolysis
by: Lisda Amalia, et al.
Published: (2025-02-01)

CLINICAL-GENETIC RISKOMETER FOR THE ISCHEMIC STROKE RISK ASSESSMENT IN ATRIAL FIBRILLATION
by: N. V. Aksyutina, et al.
Published: (2015-10-01)

A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke
by: Lin Guo, et al.
Published: (2021-02-01)

The Relationship Between Blood Omega‐3 Levels and the Small Vessel Disease in Ischemic Stroke Patients: A Case‐Control Study
by: Leila Afshar Hezarkhani, et al.
Published: (2025-04-01)

Features of the arterial hypertension clinical course in patients with ischemic heart disease and atrial fibrillation.
by: M. I. Yalovenko, et al.
Published: (2019-01-01)